These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 37702300

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
    Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD.
    JAMA Ophthalmol; 2014 Feb; 132(2):142-9. PubMed ID: 24310343
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
    Age-Related Eye Disease Study 2 Research Group.
    JAMA; 2013 May 15; 309(19):2005-15. PubMed ID: 23644932
    [Abstract] [Full Text] [Related]

  • 7. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
    Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W, AREDS2 Research Group.
    JAMA Ophthalmol; 2022 Jul 01; 140(7):692-698. PubMed ID: 35653117
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life.
    Rutjes AW, Denton DA, Di Nisio M, Chong LY, Abraham RP, Al-Assaf AS, Anderson JL, Malik MA, Vernooij RW, Martínez G, Tabet N, McCleery J.
    Cochrane Database Syst Rev; 2018 Dec 17; 12(12):CD011906. PubMed ID: 30556597
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
    Evans JR.
    Cochrane Database Syst Rev; 2006 Apr 19; (2):CD000254. PubMed ID: 16625532
    [Abstract] [Full Text] [Related]

  • 14. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
    Age-Related Eye Disease Study Research Group.
    Arch Ophthalmol; 2001 Oct 19; 119(10):1417-36. PubMed ID: 11594942
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.
    Keenan TDL, Agrón E, Keane PA, Domalpally A, Chew EY, Age-Related Eye Disease Study Research Group, Age-Related Eye Disease Study 2 Research Group.
    Ophthalmology; 2025 Jan 19; 132(1):14-29. PubMed ID: 39025435
    [Abstract] [Full Text] [Related]

  • 17. Radiotherapy for neovascular age-related macular degeneration.
    Evans JR, Igwe C, Jackson TL, Chong V.
    Cochrane Database Syst Rev; 2020 Aug 26; 8(8):CD004004. PubMed ID: 32844399
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.